bristol myers squibb has been a bright spot in a very tough market—and the stock’s move higher may just be getting started the sp 500 has been flirting with a bear market but bristol ticker bmy has gained 24 in 2022 while that gain might seem large bristol’s stock has only now returned near to where it was in august 2016 before the failure of a cancerdrug trial caused its shares to tumble and concerns about the patent expiration on its cash cow multiple myeloma treatment revlimid kept the stock under pressure